Heart valve procedures for GPs: TAVI for severe aortic stenosis — plus a lipids, aspirin & triglycerides Q&A

Speaker 1 (TAVI)

Interventional cardiologist (name not captured on the transcript) — performs TAVI and valve-in-valve procedures and says he has operated alongside cardiothoracic surgeon “Ben Anderson” (name as captured by ASR) for about 10 years.

Speaker 2 (prevention)

Cardiologist, Gold Coast Heart Centre (name not captured) — introduces himself as working at the Gold Coast Heart Centre and a private hospital whose name is garbled on the ASR (“John Quinn Valley”). A name sounding like “Christine Connor” is spoken by someone in the room, but it is unclear who it refers to.

Session context

Otter title Heart Valve Procedure Overview · id PMzYVxXmhMKkP9SIidtDeKxYq6M · ~45 min (2722 s), recorded 10 March 2026 8:04 PM AEST — the same evening as the AF ablation seminar and cardiovascular prevention table, probably one round-table event (not confirmed). Speakers are labelled “Unknown Speaker” / Speaker 1–10; slides and passed-around valve samples were not captured. No sponsor is named on this transcript.

Key messages for GPs

• Severe aortic stenosis is a mechanical problem. No tablet improves it; once severe and symptomatic, only fixing the valve helps.
• Symptomatic severe AS carries a cancer-like prognosis — the speaker quoted roughly 50% mortality at two years without intervention.
• Refer murmurs early. If you hear a murmur or the echo says moderate or severe AS, send to a cardiologist; leave the fine print (low-flow, low-gradient) to them.
• No strict age cut-off. His oldest TAVI patient was 96. Every case goes through a heart team MDT.
• After TAVI: aspirin alone is usually enough (no warfarin for a tissue valve), dental antibiotic prophylaxis is needed, and the main issues are groin/vascular complications (~5%) and new pacemakers (~5–10%).
• Lipids (second speaker): if you start a statin in a high-risk patient, go high-intensity; aim for LDL <1.8 mmol/L (high risk) or <1.4 mmol/L (very high risk/secondary prevention). Aspirin is not for routine primary prevention, even with a calcium score.

Severe aortic stenosis: why fix it

The speaker began with a naming point: he prefers TAVI (transcatheter aortic valve implantation) over the American “TAVR”, because the old valve is not removed — the new valve is implanted inside it and squashes the old, calcified leaflets against the wall.

• TAVI is a procedure for severe aortic stenosis. It is not used for pure aortic regurgitation, because without calcium there is nothing to anchor the valve and, in his words, “we do not have the right valve technology” yet. Mixed disease (stenosis plus leak) can be treated.
• The calcified valve cannot open properly, causing obstruction. Typical symptoms are exertional breathlessness and angina-like chest pain even without coronary disease; other symptoms are garbled on the ASR (dizziness/syncope is the classic third symptom — check your textbook, not the transcript).
• Two reasons to intervene: it improves quality of life and it improves survival. He quoted a two-year mortality of about 50% once patients are diagnosed with severe, symptomatic AS (“it’s like cancer”).

Transcript caveat: the ASR says “once they have become asymptomatic”, and Otter’s summary repeats “asymptomatic”. From context (and conventional teaching), the 50% figure refers to symptomatic severe AS.

Reading the echo report

A GP asked what to look for on an echo report. The speaker’s rules of thumb:

During work-up he crosses the valve with a catheter and measures a pullback gradient to confirm the echo; occasionally the readings disagree and need further thought.

Surgical, mechanical, tissue and TAVI valves

• Surgical valve replacement: open chest (like bypass surgery); the surgeon removes the old valve and sews in a new one.
• Mechanical valves last “almost forever” but need lifelong warfarin.
• Tissue (biological) valves need no warfarin but last about 10–15 years and then fail.
• TAVI valves are tissue valves on a metal frame, made from bovine (cow) pericardium cut and stitched into shape — not a cow’s actual valve. They come as balloon-expandable or self-expanding designs; the sizes he passed around were 23, 26, 29 and 31 mm. They also last roughly 10–15 years.

TAVI started because more people were living into their 80s and 90s, when open surgery is technically possible but recovery is hard. Now, in his practice, aortic valves are “pretty much exclusively” done percutaneously, and surgical numbers have fallen.

Lifetime planning and valve-in-valve

Because tissue valves wear out, age matters. A 60-year-old (he mentioned bicuspid valves as one reason younger people present) may live another 25 years — enough to need a second and possibly a third valve. The heart team weighs age, life expectancy, comorbidities and patient preference.

• Failed surgical tissue valves are now commonly treated with a valve-in-valve TAVI — he did three cases the day before, two of them valve-in-valve.
• After ~10 years of TAVI, some TAVI valves are now failing too.
• For a very young patient, one possible sequence is mechanical valve first, then (if it fails) a surgical tissue valve, then valve-in-valve.

The procedure, the MDT and who qualifies

• Heart team MDT for every patient — he described it as a requirement: interventional cardiologist, cardiothoracic surgeon, an ICU doctor and a care coordinator (at least four people), plus a rehabilitation assessment before the procedure.
• Age is not a barrier on its own. Early on, TAVI was only for people over 80–90 who were “surgical rejects”; now patients in their mid-70s and above are routine. His oldest was 96 and still doing well.
• Access: two arterial punctures — one large-bore for the delivery system (“thick hose pipes”), one for a monitoring/imaging catheter. The big artery is closed with a suture device.
• Anaesthesia: a brief general anaesthetic in his practice (others use sedation); the procedure itself is short — the transcript suggests under half an hour.
• Recovery: patients are typically up and about the next day. He described a patient with severe regurgitation of an old valve who, the morning after valve-in-valve, was “sitting up, mobilising” with “beautiful colour”.
• Mitral and pulmonary valves: mitral transcatheter work is “totally different” and he does not do it; pulmonary valve procedures are very uncommon and best done in a centre that does them regularly.

He also noted (as a side comment) that the work is poorly reimbursed for the effort involved. His annual volume is unclear on the ASR (“4050”, possibly 40–50 a year).

Complications and the GP visit a week later

Statins: hesitancy, targets and intensity

The second cardiologist ran his session as a conversation. The GPs’ first complaint: convincing patients to take a statin. “It’s almost impossible… it’s really hard to convince somebody to take a pill that will make them feel no different, possibly worse.” He noted patients’ worries about dementia (his view: statins probably do not increase — and may lower — Alzheimer’s risk) and muscle side effects amplified on social media. Calcium scores are often done to help persuade people.

• When to start: once the absolute risk calculator puts someone at intermediate-to-high or high risk; in intermediate-risk people a calcium score can help decide.
• If you start, go high-intensity to get a real therapeutic effect (the ASR suggests atorvastatin 40–80 mg; doses not clearly captured).
• “The lower the better.” He quoted the classic relationship: each 1 mmol/L fall in LDL lowers heart-attack risk by about 22%. He sees patients who stop their statin because their LDL looks “too low” — he argued low LDL is not harmful (other primates run LDLs below 1).

Young people with high LDL. A GP asked about an asymptomatic 28-year-old with high cholesterol. He had seen exactly that the day before: a young person who had stopped exercising — they agreed nothing was likely in the next ten years, so lifestyle change and long-term follow-up was reasonable. Borderline results in the very young are trickier; by the 40s with a high LDL, starting treatment is “a no-brainer” in his view. He stressed that a 10-year risk calculator can underestimate lifetime risk in young people.

PCSK9 injections and familial hypercholesterolaemia

• Many people won’t reach <1.4 on a statin alone. He discussed the two injectable PCSK9-pathway options: a fortnightly self-injected monoclonal antibody (evolocumab-type), which has cardiovascular-outcome trial data, and a six-monthly injection (inclisiran, ASR “Leqvio”), whose outcome trial had not yet reported at the time — he expected it to be positive.
• A private-script price of about $1,600 was mentioned (product and period unclear on ASR). GPs can write private scripts.
• Think familial hypercholesterolaemia (FH) with a family history of premature disease, or as soon as LDL is above about 5 mmol/L. Use the Dutch Lipid Clinic Network score — it underpins PBS criteria.
• He described a 46-year-old man with an inferior MI and LDL in the FH range who had extensive coronary disease — the kind of patient a 10-year calculator labels “low risk”.

Aspirin in primary prevention

• He might consider it in selected people around 60 (age cut-off unclear on ASR) at very high ischaemic risk and low bleeding risk — but “no good data”.
• One of those trials specifically recruited people with diabetes and still found bleeding offset the benefit.
• People with diabetes plus established cerebrovascular or peripheral vascular disease, or prior interventions, are in a different (secondary prevention) category.
• Aspirin for secondary prevention remains very important.
• He felt prevention guidelines are slow to update and mentioned an upcoming European (ESC) update.

Triglycerides, fibrates, fish oil and Lp(a)

• Triglycerides are largely dietary (and fasting matters). They add some cardiovascular risk, but most available drugs do little to change outcomes. Statins lower triglycerides somewhat and are always the first step.
• Worry when triglycerides are above ~10 mmol/L — the risk is acute pancreatitis. There is often a lifestyle driver, especially heavy alcohol. At these levels “drugs don’t work” well because the pathways are saturated; diet and alcohol are the levers.
• He described a woman drinking about a bottle of wine a day and eating out daily who presented with pancreatitis; with a very low-fat diet (“even olive oils”) and stopping alcohol her levels fell dramatically.
• Highly purified fish-oil (icosapent ethyl-type) therapy: works, but criteria are very specific (very high risk plus particular LDL and triglyceride ranges). In the trial it increased atrial fibrillation; one of his patients developed palpitations and AF and ended up in hospital.
• Fenofibrate lowers triglycerides, but outcome trials were negative for cardiovascular events.
• Lipoprotein(a): a drug in trial (ASR “Pella glass hand”, i.e. pelacarsen) lowers Lp(a), but “if it doesn’t reduce events, there’s no point… just making numbers pretty”. PCSK9 inhibitors lower it somewhat. The transcript suggests he orders Lp(a) mainly when asked (passage unclear).

Deprescribing in older people and colchicine

• Stopping statins in older patients depends on age, life expectancy and risk. For a well 85-year-old at high risk who may have another 10 years, the last thing you want is to deprescribe and see them return with an event.
• Low-dose colchicine for secondary prevention “hasn’t taken off” in his practice: diarrhoea is common and the benefit is incremental on top of standard therapy; he might think of it more in patients with inflammatory conditions.

GP clinic checklist

1. Examine for murmurs in older patients with exertional breathlessness, angina-like pain or dizziness; order an echo.
2. Refer moderate or severe AS (valve area <1 cm² or mean gradient >40 mmHg = severe) and any symptomatic patient — age alone is not a reason not to refer.
3. At the ~1-week post-TAVI visit: groin check, pulse/ECG if symptoms, confirm aspirin (or existing anticoagulant) per discharge letter, document dental antibiotic prophylaxis and recommend regular dental review.
4. Remember tissue valves last ~10–15 years: new breathlessness or murmur years later may mean valve degeneration → re-refer.
5. Statins: if treating a high-risk patient, use high intensity; target LDL <1.8 (high risk) or <1.4 (very high risk/secondary); add ezetimibe or consider PCSK9 options per PBS criteria.
6. LDL >5 or premature family history → calculate Dutch Lipid Clinic score and consider FH testing/cascade screening.
7. Do not start aspirin just because of a calcium score; reserve for secondary prevention or a documented shared decision.
8. Triglycerides >10 mmol/L → address alcohol and dietary fat urgently; discuss pancreatitis risk.

allcpd.drkotha.com · directory